Santhera Announces Closing of Exclusive North America License Agreement with Catalyst Pharmaceuticals for Vamorolone

Santhera Pharmaceuticals announces the closing of the exclusive license agreement for vamorolone in North America with Catalyst Pharmaceuticals, Inc., announced on June 20, 2023.